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INTRODUCTION INTRODUCTION
Chronic idiopathic urticaria (CIU) is manifested as widespread, short-lived (lasting less than 24 hours) weals occurring daily or almost daily for at least 6 weeks and where a predominant physical cause has been excluded. CIU is extremely disabling in its severe form and can be difficult to treat. Mast cell degranulation is of central importance in the pathogenesis of CIU. Recent reports have indicated the presence of autoantibodies in about one third of all patients with CIU. These histamine-releasing autoantibodies are directed against the ∝ subunit of the high affinity IgE receptor, F c εR 1 ∝. Patients with autoantibodies in their sera have no distinctive diagnostic clinical features though they do tend to have more severe and unremitting urticaria. [1] [2] [3] The basophil histamine release assay is currently the gold standard for detecting these functional autoantibodies in the serum of patients with chronic urticaria. However, this bioassay is difficult to standardize because it requires fresh urticaria, food and drug allergies as well as urticarial vasculitis were ruled out after taking detailed history and relevant laboratory investigations. In all patients, antihistamines were withdrawn 2 days prior to ASST. Clinical details of all patients were recorded using a standard format. Details included duration of disease in months, duration of individual weals in hours, frequency of attacks, distribution of wheals, associated systemic symptoms (fever, joint and abdominal pains), provoking physical factors, food and drug intolerance, seasonal variation and associated angioedema. Informed consent was taken from all patients. Patients were subjected to a physical provocation test and laboratory investigations based on individual history. In patients with clinical features suggestive of systemic involvement, appropriate laboratory tests were done, these included: complete blood count, urine routine examination, liver function tests (LFT), renal function tests (RFT), thyroid function tests (TFT), C3 and C4 complement level estimation and antinuclear antibody (ANA).
Methodology of ASST
Samples of 5 ml of venous blood were collected in sterile Vacutainers without a clotting accelerator and allowed to clot at room temperature for 30 min. Serum was sent to a clinical laboratory for centrifugation at 2000 rpm for 15 min. Samples of 0.05 ml of autologous serum and 0.9% sterile normal saline were separately injected intradermally into the volar aspect of the right forearm with a gap of 5 cm between injection sites. About 0.05 ml of histamine (10 µg/ ml) was injected into volar aspect of the left forearm as a positive control. Weal and flare response was measured at 30 min. ASST was deemed to be positive if a serum-induced weal which was both red and had a diameter bigger than a saline-induced response by ≥1.5 mm was seen at 30 min.
Statistical analysis
Descriptive statistics was used to summarize data for comparison between ASST-positive and ASST-negative groups. Chi Square test was used for categorical variables and the nonparametric test (Mann-Whitney test) was used for other variables as they were not distributed normally.
Observation
Out of 100 patients, 34 patients (34%) showed a positive reaction to the autologous serum test in the form of a weal and flare response, which was 1.5 mm bigger than the saline control read at 30 min [ Figure 1 ].
Clinical characteristics
Patients were categorized into two groups (ASST-positive and -negative) based on ASST, for evaluation of clinical features.
There was no significant difference in age distribution among patients with and without autoantibodies at the time of assessment [ Table 1 ]. Of a total of 100 patients, 56 were females and 44 males. Eighteen out of the 34 ASST-positive patients (52.94%) and 38 out of the 66 ASSTnegative patients (57.58%) were female.
Median duration was 12 months and 15 months in ASST positive and ASST-negative groups, respectively. There was no significant difference in the duration of disease between the two groups (Mann-Whitney Test). Wheals lasted for significantly longer duration in patients with positive ASST, the median duration being four hours for ASST-positive compared to two hours in ASST-negative individuals (P = 0.001, Mann-Whitney Test). Patients with positive ASST had more frequent attacks which was statistically significant compared to the ASST-negative group (P = 0.038, MannWhitney Test) [ Table 2 ]. Of the total 100 patients, 32 patients showed a positive challenge test for simple dermographism, which occurred more frequently in ASST-negative patients (29/32) than in those who were ASST-positive (3/32) (P < 0.001, Fischer's Exact Test). Sixty eight of 100 patients gave details regarding the affected sites. There was no significant difference between ASST-positive and -negative patients regarding the affected sites (Mann-Whitney Test). Abnormal TFT was obtained in 5/20 patients, three of these patients had positive ASST (no significant correlation with the ASST results, Chi-Square Test). ANA was done for 10/100 patients and was positive for one patient.
DISCUSSION DISCUSSION
The present study has evaluated patients with chronic idiopathic urticaria (CIU) by autologous serum skin testing and compared the clinical features of patients with positive and negative ASST results. The proportion of patients with CIU who showed a positive reaction to ASST was 34%, which is comparable with earlier reports [ Table 3 ].
Sabroe et al. found evidence of functional autoantibodies in 31% of 107 patients with chronic urticaria. [5] Zweiman et al. reported basophil histamine releasing activity in 30% of 70 chronic urticaria sera [6] while Tong et al. found that 52% of 50 chronic urticaria sera released histamine from basophils. [7] It is now established that circulating autoantibodies against the high affinity IgE receptor (F c ER 1 ) or against IgE can be found in approximately one third of all patients with CIU. [1] That these autoantibodies are functional has been demonstrated both in vivo and in vitro by induction of a weal and flare response to an intradermal injection of serum (ASST) and basophil and mast cell histamine release assays respectively. In addition, removal of autoantibodies by plasmapheresis has been shown to produce clinical improvement in patients with CIU. [2] The clinical features of patients with CIU were defined in several studies before the identification of autoantibodies. [8, 9] Now it is known that there are at least two subsets of patients with CIU -those with and without autoantibodies.
In the present study, the same investigator has recruited the patients and done the test. Thus, there is a possibility of bias due to lack of blinding. However, since the test interpretation was clear-cut and unambiguous, we feel this would not significantly affect the results. Sabroe et al. compared clinical features of patients with and without autoantibodies and concluded that patients with autoantibodies in their sera have more severe and unremitting urticaria.
The median duration of disease was 12 and 15 months for ASST-positive and -negative patients respectively, which was not statistically significant compared to the previous study by Sabroe et al. Lesions lasted for significantly longer durations in patients with a positive ASST, median duration being four hours when compared to two hours in ASST-negative individuals (P = 0.001). Patients with a positive ASST had more frequent attacks, which was statistically significant compared to the ASST-negative group (P = 0.038). Majority of patients (24/34) with positive ASST had almost daily attacks.
A study done by Sabroe et al. [5] concluded that patients with autoantibodies in their sera have more severe attacks according to several parameters including frequency, duration of individual episodes and sites involved. This is in concordance with our study, which noted frequent longlasting episodes in ASST-positive patients.
Angioedema occurred in 15 of our 100 patients. In a similar study done by Sabroe et al. angioedema occurred in 93 out of 107 cases. In both the studies, there was no significant difference between ASST-positive or -negative patients in the incidence, duration, frequency or distribution of angioedema.
There was no significant difference between ASST-positive or -negative patients regarding sites affected or diurnal variation. Majority of patients (90%) had generalized lesions involving the trunk and extremities.
Of the total 100 patients, 32 patients showed a positive challenge test for dermographism. Dermographism occurred more frequently in 29/32 ASST-negative patients than in those (3/32) who were ASST-positive (P < 0.001). Dermographic subjects comprise a special group. They do not have autoantibodies according to in vitro tests but manipulation of skin while injecting the sample may cause a weal and flare response regardless of the substance injected and may be taken as false positive responses. [4] ASST-positive patients had significantly more systemic symptoms in a study by Juhlin. [9] In particular, gastrointestinal symptoms and flushing occur more frequently in patients with autoantibodies. [9] Our study failed to reveal such associations.
Autoimmune diseases like thyroid disease, vitiligo, diabetes mellitus, pernicious anemia and rheumatoid arthritis were reported more commonly in patients with autoimmune urticaria. [5, 10] In our study, out of ten patients tested, ANA was positive in one patient who also had positive ASST. Although a higher frequency of autoimmune disease has been reported in patients with autoimmune urticaria by O' Donnel et al. [10] we did not find an increased incidence of other autoimmune diseases in our clinical study.
Abnormal TFT values were detected in three ASST-positive patients. The association of chronic urticaria with thyroid autoimmunity has been studied by Leznoff et al. [11] and it has been postulated that thyroid autoimmunity may play a role in the pathogenesis of chronic urticaria and angioedema. However, in contrast with previous studies, [11] we did not find any difference in the incidence of thyroid disease. This is likely to be because an insufficient number of patients was included for the study of a disease of low incidence (thyroid autoimmunity) or because TFT and thyroid autoantibodies were not routinely measured for all patients. Thus, TFT alone is not enough to rule out thyroid disease and the thyroid antibody test should be carried out in all CIU patients. Hence, patients with autoimmune urticaria have no distinctive, diagnostic clinical or histopathological features, which differentiate them from nonautoimmune cases although they tend to have more severe urticaria.
In our setting, ASST is the only available test for the diagnosis of autoimmune urticaria. It is a simple, inexpensive, semiinvasive and easy-to-perform test which can be done and recorded by the dermatologist himself to determine whether the patient's CIU is autoimmune in origin. As conventional approaches of management may be unsuccessful, ASST is especially important from the therapeutic point of view as it can help the dermatologist to commit himself to initiate immunosuppressive therapy in such patients.
